Does informing people who inject drugs of their hepatitis C status influence their injecting behaviour? Analysis of the Networks II study

Abstract Background People who inject drugs (PWID) are at risk of hepatitis C virus (HCV). It is plausible that PWID who receive a diagnosis of HCV will reduce their injecting risk out of concern for their injecting partners, although evidence for this is currently limited. The aim of this study was...

Full description

Saved in:
Bibliographic Details
Published in:The International journal of drug policy Vol. 25; no. 1; pp. 179 - 182
Main Authors: Aspinall, E.J, Weir, A, Sacks-Davis, R, Spelman, T, Grebely, J, Higgs, P, Hutchinson, S.J, Hellard, M.E
Format: Journal Article
Language:English
Published: Netherlands Elsevier B.V 01-01-2014
Elsevier Science Ltd
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background People who inject drugs (PWID) are at risk of hepatitis C virus (HCV). It is plausible that PWID who receive a diagnosis of HCV will reduce their injecting risk out of concern for their injecting partners, although evidence for this is currently limited. The aim of this study was to investigate whether informing PWID of their HCV diagnosis was associated with a change in injecting behaviour. Methods Prospective, longitudinal study of PWID recruited from street drug markets across Melbourne, Australia. Interviews and HCV testing were conducted at 3-monthly intervals. The association between receiving a diagnosis of HCV and (i) injecting frequency and (ii) injecting equipment borrowing, was examined using generalized estimating equations (GEE) analysis. Results Thirty-five individuals received a diagnosis of HCV during the study period. Receiving a diagnosis of HCV was associated with a decrease of 0.35 injections per month ( p = 0.046) but there was no change in injecting equipment borrowing ( p = 0.750). Conclusions A small reduction in injecting frequency was observed in PWID who received a diagnosis of HCV. This finding should be investigated further in larger studies examining a wider range of injecting risk behaviours.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0955-3959
1873-4758
DOI:10.1016/j.drugpo.2013.08.005